Shares of Moderna (NASDAQ:MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence.
The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic. However, this week, the company got good news with a mention of mRNA vaccines at the Project Stargate announcement and a new contract with the European Union.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.
Incoming AI vaccines?
Moderna works on mRNA vaccines, which use synthetic code to instruct the body to make specific proteins to fight a disease. The company is currently working on vaccines for RSV and the seasonal flu, as well as some rare diseases. However, right now, it is still seeing stagnating sales as fewer and fewer people get the mRNA vaccine for COVID-19. This is the key reason Moderna stock is in a 90% drawdown.
Nevertheless, artificial intelligence (AI) developments may supercharge the mRNA vaccine industry. At least, that's what Oracle CEO Larry Ellison believes.
Ellison mentioned using AI to help rapidly develop new vaccines as a benefit of Project Stargate, which is investing upwards of $500 billion in AI infrastructure in the United States over the next few years. Investors took this as a positive sign for Moderna stock, especially given that it could be an AI beneficiary. If you can use AI to make custom vaccines and cures for cancer, that could be a tremendous value to society and Moderna's business.
More important in the near term, Moderna announced today that it has been awarded a contract with the European Union for COVID-19 vaccinations. This should help with revenue growth and is another reason Moderna's stock popped this week.
Should you buy Moderna stock?
Moderna stock is at a crossroads. Its market cap is down to $15 billion. Compared to revenue of $5 billion and $9 billion in cash on the balance sheet, Moderna is an interesting opportunity for a turnaround bet at current prices. It isn't earning much at the moment, with a small operating loss last quarter, but there is a ton of potential with its incoming vaccines and the long-term potential to supercharge its business with AI growth.
If you are a believer in mRNA technology, now may be a perfect time to load up on some Moderna stock. It could benefit from AI developments and is trading at a cheap price. The stock is not risk-free but could be a great long-term winner for those who buy and hold.
Should you invest $1,000 in Moderna right now?
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $874,051!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of January 21, 2025
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Oracle. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.